WCLC 2025 - Posters & ePosters-EP.06.70 Development and Clinical Application of Ultra-Sensitive Digital EV Assay Targeting GLUT1 for Early Diagnosis of Non-Small Cell Lung Cancer

EP.06.70 Development and Clinical Application of Ultra-Sensitive Digital EV Assay Targeting GLUT1 for Early Diagnosis of Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study from Nagoya University presents the development and clinical application of an ultrasensitive digital extracellular vesicle assay (UDA) targeting GLUT1 for early detection of non-small cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer deaths worldwide, with poor survival rates when diagnosed late. Early detection can significantly improve outcomes, motivating the need for sensitive diagnostic methods.<br /><br />The researchers isolated intratumoral extracellular vesicles (EVs) from lung adenocarcinoma, squamous cell carcinoma, and normal lung tissue from the same patients. Proteomic analysis using tandem mass tag labeling identified candidate lung cancer-specific EV surface proteins through integration with The Cancer Genome Atlas (TCGA) gene expression data and the Human Protein Atlas (HPA). GLUT1 was selected as a promising biomarker.<br /><br />The team developed an ultrasensitive digital EV assay employing tyramide signal amplification to detect rare EV surface proteins in plasma. Testing plasma samples from 38 NSCLC patients (including stage I cases) and 9 non-cancer controls demonstrated the assay’s capability to distinguish cancer-derived EVs.<br /><br />Compared to circulating tumor DNA (ctDNA) assays, which detect cell-free DNA from dead cancer cells, this EV-based liquid biopsy captures components from viable cancer cells, including DNA, RNA, proteins, and metabolites, offering higher sensitivity.<br /><br />In conclusion, by combining tissue EV proteomics with an ultrasensitive detection platform, the study establishes a novel liquid biopsy technique capable of detecting extremely low-abundance EV surface proteins like GLUT1. This approach holds promise for early lung cancer diagnosis and may advance precision medicine by enabling biomarker discovery and noninvasive monitoring of NSCLC. Further validation and clinical application could improve lung cancer patient outcomes through earlier intervention.

Asset Subtitle

Taketo Kato

Meta Tag

Speaker Taketo Kato

Topic Pathology and Biomarkers

Keywords

ultrasensitive digital extracellular vesicle assay

GLUT1

non-small cell lung cancer

early detection

lung adenocarcinoma

squamous cell carcinoma

tyramide signal amplification

liquid biopsy

circulating tumor DNA

proteomic analysis